EuBiologics Co

EuBiologics Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of EuBiologics Co (206650.KQ) as of Nov 2, 2026 is 77.90 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 164.22 % — a change of -52.57% (lower).

FCF Conversion

77.90 %

YoY

-52.57%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of EuBiologics Co is 2025 77.90 % . FCF Conversion Rate (FCF/EBITDA) of EuBiologics Co was 2024 164.22 % . It decreases by -52.57% lower compared to the previous year.

The EuBiologics Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-577.04 KRW
Jan 1, 2019
1,677.66 KRW
Jan 1, 2020
18.05 KRW
Jan 1, 2021
60.79 KRW
Jan 1, 2022
1,710.46 KRW
Jan 1, 2023
123.97 KRW
Jan 1, 2024
164.22 KRW
Jan 1, 2025
77.90 KRW
The EuBiologics Co FCF Conversion history
YEARFCF ConversionYoY
77.90 %-52.57%
164.22 %+32.47%
123.97 %-92.75%
1,710.46 %+2,713.94%
60.79 %+236.83%
18.05 %-98.92%
1,677.66 %-390.73%
-577.04 %-392.78%
197.09 %+217.99%
61.98 %-73.44%
233.38 %+527.54%
37.19 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

EuBiologics Co Stock analysis

What does EuBiologics Co do? EuBiologics Co Ltd, headquartered in Seoul, South Korea, operates in the Health Care sector, specializing in biotechnology. The company develops and manufactures biopharmaceutical products, with operations divided into two segments: the Vaccine segment, focusing on oral cholera vaccines, and the Contract Research and Manufacturing Organization (CRMO) segment, providing research and manufacturing services for biopharmaceuticals. Listed on January 24, 2017, EuBiologics employs 323 people. EuBiologics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about EuBiologics Co stock

FCF Conversion Rate (FCF/EBITDA) of EuBiologics Co is 77.90 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of EuBiologics Co changed from 164.22 % to 77.90 %, representing a -52.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) EuBiologics Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s EuBiologics Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — EuBiologics Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — EuBiologics Co